Jorge Carlos Santos da Costa

Jorge Carlos Santos da Costa

Auto-generated profile, based on publicly available information

Jorge Carlos Santos da Costa

Fundação Oswaldo Cruz, Brasil

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
SLSIlvana Leite
SIlvana Leite
JBJorge Antonio Zepeda Bermudez
Jorge Antonio Zepeda Bermudez
DMDébora Melecchi
Débora Melecchi
AVAdelir Rodrigues da Veiga
Adelir Rodrigues da Veiga
AOAna Liani Beisl Oliveira
Ana Liani Beisl Oliveira
JCJorge Carlos Santos da Costa
Jorge Carlos Santos da Costa
Resumo A 16ª Conferência Nacional de Saúde demonstrou o interesse do controle social em intervir sobre as políticas públicas a fim de garantir o direito às tecnologias de saúde. O projeto Integra - Integração das Políticas de Vigilância em Saúde, Assistência Farmacêutica, Ciência, Tecnologia e Inovação em Saúde -, nasce da parceria entre o Conselho Nacional de Saúde, a Escola Nacional dos Farmacêuticos e a Fundação Oswaldo Cruz (Fiocruz), com apoio da Organização Pan-Americana de Saúde (OPAS) com objetivo de fortalecimento da participação e engajamento social na temática e a integração das políticas e práticas de saúde em diferentes setores da sociedade (movimentos sociais, controle social e profissionais de saúde), tendo as diversas etapas relacionadas ao acesso aos medicamentos (pesquisa, incorporação, produção nacional e serviços) como mote principal, no cenário da pandemia de COVID-19. Oferta-se, neste projeto, capacitação para grupos de lideranças nas regiões de saúde e atividades de grande abrangência nacional e política. Espera-se alcançar o estabelecimento de uma rede intersetorial, integrada de lideranças capazes de atuar colaborativamente para a defesa do desenvolvimento da ciência, das políticas públicas, da soberania nacional e do controle social da saúde.

1 January 2026 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
NRNorberto Rech
Norberto Rech
JBJorge Antonio Zepeda Bermudez
Jorge Antonio Zepeda Bermudez
JCJorge Carlos Santos da Costa
Jorge Carlos Santos da Costa
MFMareni Rocha Farias
Mareni Rocha Farias
Resumo O ano de 2024 marca os vinte anos da vigência da Política Nacional de Assistência Farmacêutica (PNAF), a qual envolve ações de promoção, proteção e recuperação da saúde, tendo o acesso da população aos medicamentos e seu uso racional como parte essencial dos seus princípios. Essa política intersetorial é estratégica para a inclusão das demandas do SUS na agenda dos demais setores com impactos no campo da saúde, incluindo aqueles integrantes do Complexo Econômico-Industrial da Saúde (CEIS). Dadas as suas características, o objetivo do presente estudo foi identificar as permeações da PNAF nas políticas públicas relacionas ao CEIS, entre os anos 2004 e 2024, visando contribuir para o aprimoramento de tais políticas. Adotou-se o modelo desenvolvido por Walt e Gilson (1994) para análise de políticas públicas, com identificação de contextos proposta por Araújo Júnior e Maciel Filho (2001) e tipologia de políticas proposta por Walt (1994). Os resultados evidenciaram permeações dos princípios e eixos estratégicos da PNAF em 17 políticas setoriais relacionadas ao CEIS e à saúde no período de 20 anos, com destacadas invisibilidades no período de 2017 a abril de 2023.

24 August 2026 in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
Verified
Journal Article
Open access
VSVirginia Luiz de Sousa
Virginia Luiz de Sousa
JCJorge Carlos Santos da Costa
Jorge Carlos Santos da Costa
ELElezer Monte Blanco Lemes
Elezer Monte Blanco Lemes
Introduction: Public procurement of oncology medicines represents a significant share of healthcare expenditures and plays a crucial role in ensuring universal access to essential therapies. However, the bidding process is subject to failures that compromise efficiency, transparency, and patient safety. Objectives: To develop and apply a risk management (RM) model adapted to the reality of public procurement of oncology medicines, based on nationally and internationally recognized methodologies. Method: Case study of an applied, exploratory, and descriptive nature, with a qualitative approach, grounded in bibliographic and documentary research and direct observations. Techniques such as process mapping, SWOT analysis, brainstorming, and adapted FMEA were used, integrated with the guidelines of ABNT NBR ISO 31000:2018, ABNT NBR IEC 31010:2021, and the Brazilian Federal Comptroller General’s Risk Management Manual (CGU, 2018). Results: A total of 65 hazards were identified in the routines of anticancer drug procurement. The control measures led to a positive reclassification of risks, with a significant shift from the most critical levels to categories of lower impact. Among the 65 identified hazards, 23 were classified as low risk, 35 as medium, 6 as high, and 1 as very high. After the implementation of the control measures, a marked improvement in the risk profile was observed, with 53 events classified as low risk, 9 as medium, 3 as high, and no events as very high risk. These results demonstrate the effectiveness of the actions, achieving the complete elimination of very high risks and a reduction greater than 70% in medium and high risks. Conclusions: The proposed model demonstrated potential to enhance governance, transparency, and efficiency in the public procurement of oncology medicines, in addition to contributing to the sustainability of the SUS.

12 December 2025 in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
Verified
Journal Article
Open access
PDF file
RRRodrigo Fonseca da Silva Ramos
Rodrigo Fonseca da Silva Ramos
BCBeatriz Borges Correa
Beatriz Borges Correa
AMAmanda de Oliveira Esteves Moreira
Amanda de Oliveira Esteves Moreira
Alessandra ViçosaAlessandra Viçosa
Alessandra Viçosa
JCJorge Carlos Santos da Costa
Jorge Carlos Santos da Costa
Introduction: The application of three-dimensional printing technology (3DP) has gained notoriety as an alternative to the traditional manufacturing model in the production of medicines, enabling the development of personalized medicines for each patient. Objective: To consolidate the currently available information regarding the regulatory perspectives on the use of 3DP in pharmaceutical manufacturing and to discuss the challenges that must be addressed to enable its broad adoption. Method: This work consists of an integrative literature review in the National Library of Medicine (PubMed) and Web of Science covering the period from December 2019 to December 2024, which approaches the regulatory basis that guide the application of 3DP in the medicine production, in comparison with the traditional production methods, and what are the main gaps and challenges associated with these regulations. Results: The evaluated articles highlight the need of establishing specific regulations focused on the quality and manufacturing sites of medications produced by 3DP, to enable their adoption as an option for supplying personalized medicines. The results reported in this review show that the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Medicines & Healthcare products Regulatory Agency (MHRA) have adopted monitoring of new technologies and advising institutions as a way of enabling the introduction of these medicines in the market and prepare new regulations. Conclusions: The information in this article serves as a preliminary basis to understand the existing regulatory challenges in relation to 3DP of medicines and provide a vision of the scenarios that are being proposed for this technology insertion.

13 December 2024 in Vigilância Sanitária Em Debate: Sociedade, Ciência & Tecnologia
Verified
Journal Article
Open access
PDF file
STSebastián Tobar
Sebastián Tobar
JCJorge Carlos Santos da Costa
Jorge Carlos Santos da Costa
MGMirian Nakamura Gouvea
Mirian Nakamura Gouvea
MMMarco Alberto Medeiros
Marco Alberto Medeiros
IDIsabella Fernandes Delgado
Isabella Fernandes Delgado
Introduction: This paper reports on the experience of the Vaccine Development and Production Course, an initiative promoted by Fiocruz within the framework of the MERCOSUR Health Ministers’ Meetings. The experience was developed in the second half of 2023, with the participation of students from Argentina, Brazil, Paraguay, and Uruguay as member states of the bloc and Chile as an associate state. Objective: To support the hypothesis that we will only be able to advance health sovereignty in the field of vaccines if we simultaneously implement sovereignty in terms of strategy and the process of training human resources, articulating the region’s capabilities in a network. Method: This is a report that presents reflections onhealth sovereignty in the production of biological products, based on a training experience that involved the mobilisation of existing capacities at Fiocruz, Instituto Butantan and Nortec, based on synchronous remote classes and personal technical visits. Results: Details of this experience were presented and based on this, we sought to outline appropriate strategies for continuing professional development in the region, with the aim of achieving health sovereignty in terms of regional vaccine production with a view to self-sufficiency. Conclusions: It is noted that despite the language barriers and institutional differences between the bloc and the associated countries, the evaluation carried out at the end of the course confirms the relevance and the need to expand experiences such as the one developed. The need to create capacities in the region to effectively achieve health sovereignty is evident, as well as the importance of incorporating some strategic themes identified by the students to continue the qualification of professionals in the region, in a continuous and permanent training process.

1 January 2026 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
SLSIlvana Leite
SIlvana Leite
FMFernanda Manzini
Fernanda Manzini
JCJorge Carlos Santos da Costa
Jorge Carlos Santos da Costa
JBJorge Antonio Zapeda Bermudez
Jorge Antonio Zapeda Bermudez